文献速递治疗药物监测与药物基因组学

利匹韦林治疗药物监测在HIV患者病毒学应答与耐药中的价值

Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-01

本研究为多中心回顾性队列,纳入379例接受利匹韦林/恩曲他滨/替诺福韦DF方案初治或经治HIV患者,随访中位28个月。发现病毒学失败者利匹韦林谷浓度显著低于抑制者,ROC确定最佳目标谷浓度为70 ng/mL(敏感性75.4%,特异性61.5%)。

要点

  • 病毒学失败者利匹韦林谷浓度显著低于病毒抑制者
  • ROC确定最佳谷浓度目标为70 ng/mL
  • 临床可考虑提高利匹韦林谷浓度目标

核心结论

  • 利匹韦林血浆谷浓度影响病毒学应答和耐药突变出现,建议临床采用更高谷浓度目标。

研究设计与样本

  • 多中心回顾性队列研究,纳入379例接受利匹韦林/恩曲他滨/替诺福韦DF每日一次方案的初治和经治HIV患者。

主要发现

  • 中位随访28个月,26%患者停药(主要为毒性),病毒学成功率65.7%,病毒学失败率5%。
  • HIV-RNA>40 copies/mL患者中,M6时28%、M12时31%利匹韦林谷浓度低于50 ng/mL阈值,且中位谷浓度显著低于病毒抑制者。
  • 获得利匹韦林耐药突变的病毒学失败患者中,一半至少有一次谷浓度不达标。
  • ROC分析确定最佳谷浓度目标为70 ng/mL(敏感性75.4%,特异性61.5%)。

关键数值与推荐

  • 当前 efficacy 阈值为50 ng/mL。
  • ROC确定的最佳目标谷浓度为70 ng/mL,敏感性75.4%,特异性61.5%。

临床怎么用

  • 对接受利匹韦林方案者监测谷浓度,关注低于50 ng/mL者,可考虑以70 ng/mL为目标调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The purpose of this study was to assess the antiviral activity of the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination and to describe the pharmacokinetics of rilpivirine and its association with resistance in clinical routine. METHODS: A retrospective multicentre cohort study was performed in both naive and pretreated HIV patients receiving the once-daily rilpivirine/emtricitabine/tenofovir disoproxil fumarate regimen. Immuno-virologic and resistance data, and rilpivirine plasma trough concentrations were collected over the follow-up. Statistical analyses were performed to evaluate the relationship between rilpivirine pharmacokinetics and virological response. Receiver operating characteristic (ROC) curve analysis was performed to determine the best target rilpivirine trough concentration. RESULTS: Overall, 379 patients were included. After a median follow-up of 28 months, 26% of patients discontinued mainly due to toxicity and the virological success rate was 65.7%. Virological failure occurred in 5% of patients. A significant proportion of patients with HIV-RNA > 40 copies/mL displayed rilpivirine plasma trough concentrations below the currently used 50 ng/mL efficacy threshold at both M6 (28%) and M12 (31%), in agreement with a significant lower median rilpivirine plasma trough concentration compared with patients virologically suppressed. Half of the patients with virologic failure who acquired rilpivirine resistance mutations had at least one suboptimal rilpivirine trough concentration. The optimal target for rilpivirine trough concentration was 70 ng/mL (sensitivity 75.4%; specificity 61.5%). CONCLUSIONS: This study shows the impact of rilpivirine plasma trough concentration on both virological response and the emergence of rilpivirine mutations. Moreover, our results suggest that a higher target of rilpivirine trough concentration could be proposed in clinical practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Néant N, Lê MP, Bouazza N, et al. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. Br J Clin Pharmacol. 2020. PMID: 32374049. doi:10.1111/bcp.14344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。